United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

Korea Investment CORP grew its stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 6.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 39,289 shares ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

In our case, the sole barrier identified by the FDA was the new clinical exclusivity granted to TYVASO DPI, which expires on May 23, 2025. As directed in the tentative approval label, we plan to ...

Good morning and welcome everyone to the Liquidia Corporation full year 2024 financial result and corporate update conference call. My name is Shannon, and I will be your conference operator today.

After being in the green for a few trading sessions, the broader market index slid 0.8% on Wednesday, and blue-chip companies ...

To date, participants have safely titrated to the study’s maximum dose twice daily, which is comparable to 26-28 breaths of Tyvaso® administered four times per day. The FDA has confirmed that a single ...

Commonwealth Equity Services LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 3.7% during ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...

Following the presentations, each poster will be available on the Publications page of Liquidia's website at https://liquidia.com/publications.